Predict your next investment

Corporation
preveceutical.com

See what CB Insights has to offer

Partners & Customers

2

About PreveCeutical Medical

PreveCeutical Medical is a health sciences company that develops options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical Medical Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PreveCeutical Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find PreveCeutical Medical in 1 Expert Collection, including Cannabis.

C

Cannabis

3,613 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Latest PreveCeutical Medical News

PreveCeutical Receives AU$315,338 Research & Development Tax Incentive Cash Refund

Aug 31, 2021

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received a AU$315,338 cash rebate from the Australian Federal Government's Research and Development ("R&D") Incentive Program. The cash refund is related to expenditure on eligible Australian R&D activities conducted during the financial year ended December 31, 2020. The R&D activities were across PreveCeutival's portfolio, including the Sol-gel nose-to-brain drug delivery system and the non-addictive analgesics programs, conducted at the University of Queensland, Australia. This funding will support and reinforce the Company's continued investments in its R&D program, protecting the intellectual property derived from the programs, and developing marketable products. The R&D tax incentive encourages companies to engage in R&D programs that have the potential to improve global health outcomes while generating economic benefits locally. PreveCeutical's Chair and Chief Executive Officer, Mr. Stephen Van Deventer, stated, "We appreciate the tax credit we have received. This continues to fund our research and development without dilution of the Company's capital. This funding will add to our Company's working capital and will go towards the patent, licenses and R&D costs." About PreveCeutical PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences. The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders;. Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook . On behalf of the Board of Directors Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact: Stephen Van Deventer: +1 604 306 9669 Or, Investor Relations ir@preveceutical.com Forward-Looking Statements: This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including the Company's anticipated business plans, and the prospect of its ability and success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "will" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors, including risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialize therapeutic and diagnostic technologies, pursue business partnerships, complete its research programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at www.sedar.com . Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94991 Sign up for Alerts Sign up to receive news releases by email for PreveCeutical Medical Inc. or all companies belonging to the Pharmaceuticals, Health, Biotechnology industries.

PreveCeutical Medical Acquisitions

1 Acquisition

PreveCeutical Medical acquired 1 company. Their latest acquisition was Penta 5 Group on October 05, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/5/2018

Acquired

2

Date

10/5/2018

Investment Stage

Companies

Valuation

Total Funding

Note

Acquired

Sources

2

PreveCeutical Medical Partners & Customers

2 Partners and customers

PreveCeutical Medical has 2 strategic partners and customers. PreveCeutical Medical recently partnered with Invictus on .

Date

Type

Business Partner

Country

News Snippet

Sources

Vendor

Invictus

Italy

PreveCeutical Medical Inc. PreveCeutical Logo 2017 PreveCeutical Engages Invictus Resources to Provide Investor Awareness Services.

Vancouver , British Columbia : PreveCeutical Medical Inc. -LRB- the `` Company '' or `` PreveCeutical Medical Inc. '' -RRB- -LRB- CSE : PREV , : PRVCF , FSE : 18H -RRB- , announces that it has entered into a Master Services Agreement dated effective October 1 , 2018 -LRB- the `` Agreement '' -RRB- with World Wide Holdings LLC , DBA Invictus Resources -LRB- `` Invictus '' -RRB- , whereby Invictus will provide investor awareness services -LRB- the `` Services '' -RRB- to the Company involving the selection and coordination of investor awareness providers and services .

1

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

Type

Vendor

Partner

Business Partner

Invictus

Country

Italy

Subscribe to see more

News Snippet

PreveCeutical Medical Inc. PreveCeutical Logo 2017 PreveCeutical Engages Invictus Resources to Provide Investor Awareness Services.

Vancouver , British Columbia : PreveCeutical Medical Inc. -LRB- the `` Company '' or `` PreveCeutical Medical Inc. '' -RRB- -LRB- CSE : PREV , : PRVCF , FSE : 18H -RRB- , announces that it has entered into a Master Services Agreement dated effective October 1 , 2018 -LRB- the `` Agreement '' -RRB- with World Wide Holdings LLC , DBA Invictus Resources -LRB- `` Invictus '' -RRB- , whereby Invictus will provide investor awareness services -LRB- the `` Services '' -RRB- to the Company involving the selection and coordination of investor awareness providers and services .

Subscribe to see more

Subscribe to see more

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.